Abstract
Background: Experimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored.
Objective: To discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury.
Results: Existing therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide.
Conclusion: Studies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.
Keywords: Myocardial infarction, myocardial reperfusion injury, ischemic conditioning, cardiac pharmacology, clinical trial.
Graphical Abstract
Current Drug Targets
Title:Progress in Therapies for Myocardial Ischemia Reperfusion Injury
Volume: 18 Issue: 15
Author(s): Hong-jie Chi, Mu-lei Chen, Xin-chun Yang, Xiang-min Lin, Hao Sun, Wen-shu Zhao, Dan Qi, Jia-lu Dong and Jun Cai*
Affiliation:
- Department of Cardiology, Chaoyang Hospital, Capital Medical University, and Beijing Key Laboratory of Hypertension Research, Beijing, 100020,China
Keywords: Myocardial infarction, myocardial reperfusion injury, ischemic conditioning, cardiac pharmacology, clinical trial.
Abstract: Background: Experimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored.
Objective: To discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury.
Results: Existing therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide.
Conclusion: Studies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.
Export Options
About this article
Cite this article as:
Chi Hong-jie, Chen Mu-lei, Yang Xin-chun , Lin Xiang-min, Sun Hao, Zhao Wen-shu, Qi Dan, Dong Jia-lu and Cai Jun*, Progress in Therapies for Myocardial Ischemia Reperfusion Injury, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450117666160401120308
DOI https://dx.doi.org/10.2174/1389450117666160401120308 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Modulation of MMP-9 Pathway by Lycopene in Macrophages and Fibroblasts Exposed to Cigarette Smoke
Inflammation & Allergy - Drug Targets (Discontinued) Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Cyclodextrins as Food Additives and in Food Processing
Current Nutrition & Food Science Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits
Vascular Disease Prevention (Discontinued) Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?
Current Pharmaceutical Design Illuminating microRNA Transcription from the Epigenome
Current Genomics Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders
Current Drug Metabolism Pain and Obesity in the Older Adult
Current Pharmaceutical Design